IDRAPARINUX SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H55O49S7.9Na
Molecular Weight	1727.177
Optical Activity	UNSPECIFIED
Defined Stereocenters	25 / 25
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS([O-])(=O)=O)O[C@]([H])(O[C@H]3[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]4[C@@H](COS([O-])(=O)=O)O[C@H](OC)[C@H](OS([O-])(=O)=O)[C@H]4OS([O-])(=O)=O)O[C@H]3C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]2OS([O-])(=O)=O)O[C@@H]1C([O-])=O)O[C@H](COS([O-])(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC

InChI

InChIKey=MVPQUSQUURLQKF-MCPDASDXSA-E

InChI=1S/C38H64O49S7.9Na/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54;;;;;;;;;/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63);;;;;;;;;/q;9*+1/p-9/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-;;;;;;;;;/m1........./s1

HIDE SMILES / InChI

Molecular Formula	C38H55O49S7
Molecular Weight	1520.269
Charge	-9
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	25 / 25
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18447601 | https://www.ncbi.nlm.nih.gov/pubmed/22111528

Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.

Originator

Approval Year

PubMed

Title	Date	PubMed
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.	2008 May	18447601
Idraparinux and idrabiotaparinux.	2010 Jan	22111528

Sample Use Guides

In Vivo Use Guide

The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Sun Dec 18 20:14:25 UTC 2022` Edited by `admin` on `Sun Dec 18 20:14:25 UTC 2022`
Record UNII	H84IXP29FN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IDRAPARINUX SODIUM

Official Name

English

idraparinux sodium [INN]

Common Name

English

IDRAPARINUX SODIUM [MART.]

Common Name

English

Idraparinux sodium [WHO-DD]

Common Name

English

ORG-34006

Code

English

IDRAPARINUX SODIUM [USAN]

Common Name

English

IDRAPARINUX NONASODIUM SALT [MI]

Common Name

English

SANORG-34006

Code

English

SANORG34006

Code

English

IDRAPARINUX NONASODIUM SALT

Common Name

English

METHYL (SODIUM 2,3,4-TRI-O-METHYL-6-O-SULFONATO-.ALPHA.-D-GLUCOPYRANOSYL)-(1->4)-(SODIUM 2,3-DI-O-METHYL-.BETA.-D-GLUCOPYRANOSYLURATE)-(1->4)-(TRISODIUM 2,3,6-TRI-O-SULFONATO-.ALPHA.-D-GLUCOPYRANOSYL)-(1->4)-(SODIUM -2,3-DI-O-METHYL-.ALPHA.-L-IDOPYRANOSY

Common Name

English

Code System Code Type Description

EVMPD

SUB25406